Topical clobetasol mouthwash and photobiomodulation for pemphigus vulgaris oral lesions
Official title: Evaluation of the Effectiveness of Clobetasol Propionate 0.05% and Photobiomodulation in the Management of Oral Lesions in Patients With Pemphigus Vulgaris. (Three-arm Randomized Controlled Clinical Study)
Run by Damascus University · NCT07641725 · Data updated 2026-11-12
This study tests whether clobetasol propionate mouthwash, photobiomodulation therapy, or their combination can help heal painful oral ulcers in people with pemphigus vulgaris.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Damascus University Academic / other |
| Locations | 1 site (Damascus) |
| Status | Recruiting |
| Started | November 1, 2025 |
| Main results expected | September 1, 2026 |
| Study ends | December 1, 2026 |
| Registry record updated | June 11, 2026 |
| Trial ID | NCT07641725 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with confirmed pemphigus vulgaris and active oral erosions larger than 1 cm who are on a stable systemic corticosteroid regimen.
✕Probably not a fit
Patients with no active oral lesions, those not on stable systemic corticosteroids, or those with conditions that contraindicate topical therapies may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study compares topical clobetasol propionate mouthwash, diode laser–based photobiomodulation, and their combination in patients with pemphigus vulgaris who have active oral lesions. The goal is to see if these topical therapies can speed healing, reduce pain, and possibly lower the need for higher systemic medications. The trial uses stable systemic corticosteroid doses as a background therapy and focuses on lesions larger than 1 cm. Outcomes likely include lesion size reduction, pain scores, and safety data related to topical treatments. The study is conducted at Damascus University’s Department of Oral Medicine in Damascus, Syria.
Why it matters
Potential benefit: If successful, patients could experience faster healing of oral ulcers and reduced oral pain, with potential for lower systemic medication needs.
How similar studies have gone: Previous studies in similar mucosal conditions suggest topical therapies can aid healing, but this exact combination for pemphigus vulgaris is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Confirmed diagnosis of Pemphigus Vulgaris based on clinical presentation, histopathology, and immunopathological findings (positive direct and indirect immunofluorescence), according to World Health Organization (WHO) standards. 2. Presence of active erosive or ulcerative oral lesions with a maximum diameter exceeding 1 cm. 3. Patients currently maintained on a stable systemic corticosteroid regimen not exceeding 1 mg/kg/day. Exclusion Criteria: 1. Co-existing chronic systemic conditions, including significant gastrointestinal disorders or uncontrolled diabetes mellitus. 2. History or current evidence of malignancy. 3. Concurrent use of systemic antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), or hormonal therapies that may interfere with the study outcomes. 4. Pregnancy or active lactation. Note: These criteria are strictly enforced to ensure that the study population remains homogeneous regarding the systemic treatment protocol.
Where it's running
-
Department of Oral Medicine, Faculty of Dental medicine
Damascus, Syria Recruiting
Study contacts
- Principal investigator: Abeer Aljoujou, PhD In Oral medicine — Associate Professor, Department of Oral Medicine, Faculty of Dental medicine, Damascus University, Damascus, Syria.
- Study coordinator: Alaa Alhomsi, DDS,MSc,PhD Student
- Email: allaalhomsi1@gmail.com
- Phone: 00963993837778
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.